Hayakawa Toru, Sato Mayumi, Konaka Masako, Makino Azusa, Hirohata Tae, Totsu Sawako, Wada Yoshiko, Sato Hideki, Inotsume Nobuo, Fujita Akihisa, Sekine Kyu-ichiro
Dept. of Pharmacology and Therapeutics, Hokkaido Pharmaceutical University School of Pharmacy.
Gan To Kagaku Ryoho. 2006 May;33(5):633-8.
We performed a retrospective study that compared the efficacy and safety of ramosetron with azasetron in a case of acute and delayed emesis induced by cisplatin (CDDP)-included chemotherapy in patients with lung cancer. The study subjects were 100 lung cancer patients treated with combination therapy of cisplatin, ifosfamide, irinotecan (CIC therapy). The ramosetron group and azasetron group received, respectively, ramosetron 0.3 mg or azasetron 10 mg intravenous injection, 30 minutes prior to CDDP. All patients received 32 mg of dexamethasone intravenously. Protection from emesis showed no significant difference between two treatment groups. However, the grade of nausea was significantly lower in the ramosetron group than in the azasetron group. Furthermore, chlorpromazine hydrochloride for use as a rescue medication was required by significantly fewer in the ramosetron group than in the azasetron group. Adverse effects were observed in 27 cases in the ramosetron group and 24 cases in the azasetron group. However, because the symptoms were all mild, we did not consider there was any safety problem. In conclusion, it was suggested that ramosetron is a clinically useful treatment for acute and delayed emesis induced by cisplatin-induced chemotherapy in patients with lung cancer.
我们进行了一项回顾性研究，比较了雷莫司琼和阿扎司琼在肺癌患者顺铂（CDDP）化疗引起的急性和迟发性呕吐中的疗效和安全性。研究对象为100例接受顺铂、异环磷酰胺、伊立替康联合治疗（CIC治疗）的肺癌患者。雷莫司琼组和阿扎司琼组分别在顺铂给药前30分钟静脉注射0.3mg雷莫司琼或10mg阿扎司琼。所有患者均静脉注射32mg地塞米松。两组在预防呕吐方面无显著差异。然而，雷莫司琼组的恶心程度明显低于阿扎司琼组。此外，雷莫司琼组需要使用盐酸氯丙嗪作为解救药物的患者明显少于阿扎司琼组。雷莫司琼组有27例出现不良反应，阿扎司琼组有24例。然而，由于症状均较轻，我们认为不存在任何安全问题。总之，提示雷莫司琼是肺癌患者顺铂诱导化疗引起的急性和迟发性呕吐的一种临床有用的治疗方法。
